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The role of lymphocytes in the experimental progressive
glomerulonephritis.
Background. Glomerular accumulation of leukocytes, in-
cluding lymphocytes, is a common feature in most types
of glomerulonephritis. However, the role of lymphocytes in
progressive glomerulonephritis has not been elucidated. We
examined the role of lymphocytes in the development of pro-
gressive mesangial proliferative glomerulonephritis induced by
two injections of monoclonal antibody 1-22-3 in rats.
Methods. To elucidate the role of lymphocytes, circulating
lymphocytes were depleted using specific monoclonal antibod-
ies to rat lymphocytes prior to the induction of progressive
glomerulonephritis. The effects of lymphocyte depletion on pro-
teinuria and glomerular alterations were assessed 7 and 56 days
after the induction of progressive glomerulonephritis.
Results. Significant glomerular accumulation of CD4+T cells,
CD8+ T cells, and ED3+-activated macrophage were observed
after the induction of glomerulonephritis. Depletion studies
showed that continuous treatment with anti-CD5, anti-CD4, or
anti-CD8 treatment reduced proteinuria and ameliorated the
glomerular lesions on day 56. Depletion of CD4+ T cells also
reduced glomerular accumulation of CD8+ T cells and ED3+-
activated macrophages, and reduced glomerular expression of
mRNA for interferon-gamma (INF-c) (63.0% in anti-CD5 and
62.3% reduction in anti-CD4). Transit lymphocyte depletion
limited in early stage of progressive glomerulonephritis demon-
strated that CD4+ T-cell depletion, but not anti-CD8 treatment
prevented glomerular injuries 56 days after the induction of pro-
gressive glomerulonephritis.
Conclusion. CD4+ T cells played a central role in the
development of progressive glomerulonephritis, controlling
recruitment and activation of CD8+ cytotoxic cells and/or
macrophages.
The acute phase of proliferative forms of glomeru-
lonephritis is characterized by the glomerular infil-
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tration of inflammatory cells and the proliferation of
glomerular cells [1–4]. The density of lymphocytes and/or
macrophages accumulation is predictive of disease pro-
gression in chronic glomerular nephritis including IgA
nephropathy (IgAN) [5–7]. However, the role of lym-
phocytes in progressive glomerulonephritis has not been
clearly understood. In experimental disease models, the
critical role of CD4+ T cell [8] or CD8+ T cell [9]
have been shown to be important in inducing crescen-
tic glomerulonephritis. Our previous study showed that
CD4+ T cells are involved in the development of Thy 1.1
glomerulonephritis induced by a single injection of
anti-Thy 1.1 monoclonal antibody 1-22-3 in rat [10,
11]. Thy 1.1 glomerulonephritis is commonly used as
the model of mesangial proliferative glomerulonephri-
tis; however, this model is self-limiting, and the glomeru-
lar architecture returns to normal within 4 to 6 weeks
(reversible model). Therefore, this model is not suitable
to analyze the role of inflammatory cells in the progres-
sive glomerulonephritis.
We have also reported that two consecutive injec-
tions of monoclonal antibody 1-22-3 in an interval of
2 weeks had caused the irreversible mesangial alter-
ations (irreversible model) [12]. In this irreversible
model, a significant increase of the glomerular accu-
mulation of inflammatory cells, including lymphocytes
and macrophages, was observed. However, the role of
these cells in the disease progression has not been clearly
understood.
The aim of this study is to elucidate the role of lym-
phocytes in the irreversible mesangial alteration model
caused by two injections of monoclonal antibody 1-22-3.
We assessed the precise kinetics of glomerular and in-
terstitial accumulation of lymphocytes in the progressive
mesangial proliferative glomerulonephritis model and
examined the role of lymphocytes in the disease progres-
sion by two different protocols of lymphocyte depletion.
We have demonstrated here that a significantly higher
number of CD4+ T cell and activated macrophage were
accumulated into the glomeruli in the irreversible model.
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Furthermore, CD8+ T cells, which were not detectable
in the reversible model, also recruited into the glomeruli
in the irreversible model. Depletion studies revealed that
CD4+ T cells had an essential role not only for the de-
velopment of the mesangial alteration in the progressive
glomerulonephritis, but also for the recruitment of CD8+
T cells and the activated macrophages.
METHODS
Animals
All experiments were performed using female
Wistar rats weighing 150 to 180 g, purchased from Charles
River Japan (Atsugi, Japan). All animal experiments con-
formed to the National Institutes of Health Guide for the
Care and Use of Laboratory Animals.
Antibodies
A hybridoma producing mouse antirat Thy 1.1 mono-
clonal antibody 1-22-3 (IgG3) was purified using meth-
ods reported by Orikasa et al [13]. Briefly, a mouse
hybridoma was prepared by immunization of BALB/c
mice with collagenase-treated fresh rat glomeruli. As-
citic fluid containing monoclonal antibody 1-22-3 was
produced in BALB/c mice primed with 2,6,10,14-
tetramethylpentadecane (Sigma Chemical Co., St. Louis,
MO, USA) and injected intraperitoneally with the
hybridoma prepared as above. This fluid was sub-
jected to 50% ammonium sulfate precipitation and the
immunoglobulin-rich fraction thus obtain was dialyzed
against phosphate-buffered saline (PBS). Mouse anti-
rat monoclonal antibody OX-19 (IgG1), which recog-
nizes rat CD5 antigen, was used to detect and deplete
pan T cells [10, 14]. OX-38 (IgG2a), which recognizes
CD4+ helper T cells, was used to detect and deplete
CD4+ T cells [15, 16]. OX-8 (IgG1), which recognizes
CD8+ T cytotoxic/suppressor and natural killer (NK)
cells, was used to detect and deplete all CD8+ cells
[15, 17]. 10/78 (IgG1), which recognizes rat CD161 anti-
gen (also as known as NKR-P1), was used to detect
NK cells [18]. OX-19, OX-38, and OX-8 were precip-
itated from ascites using the corresponding hybridoma
(European Collection of Animal Cells, Porton Down, Sal-
isbury, UK). 10/78 was purchased from Serotec (Oxford,
UK). Murine IgG1 monoclonal antibody, RVG1, which
recognizes rotavirus and does not react with rat tissue,
was used as a control antibody [13]. G28 (IgG2a, anti-
CD8) (BD Biosciences, San Jose, CA, USA) was used
as another marker of CD8+ cells for double labeling
immunofluorescence study [19]. ED1 (IgG1), which rec-
ognizes pan monocytes/macrophages, and ED3 (IgG2a),
which recognizes rat CD169 antigen (also as known as
sialoadhesin) expressed by activated macrophages, were
purchased from Chemicon International Inc. (Temecula,
CA, USA) and Serotec, respectively [20, 21]. Tri-Color
(R-PE-Cy5 Tandem)-conjugated monoclonal antibody
OX-30 (IgG1) (Caltag, Burlingame, CA, USA), which
recognizes leukocyte common antigen was used to detect
total leukocytes on flow cytometric analysis [22]. Rabbit
antirat collagen type I antibody and anti-a-smooth mus-
cle actin (a-SMA) monoclonal antibody 1A4 (IgG2a),
were purchased from Chemicon and Sigma, respectively.
Fluorescein isothiocyanate (FITC)-conjugated goat an-
timouse IgG1 (Southern Biotechnology Associates,
Birmingham, AL, USA), FITC-conjugated goat an-
timouse IgG2a (Southern Biotechnology Associates),
and FITC-conjugated swine antirabbit immunoglobu-
lins (Dako, Glostrup, Denmark) were used as secondary
antibodies.
Experimental protocol
Experiment 1: Examination of glomerular infiltration of
lymphocytes. Animals were divided into two groups and
were first injected with 1.0 mL of saline (reversible group)
or 1.0 mL of saline containing 0.5 mg monoclonal anti-
body 1-22-3 (irreversible group) intravenously through
the tail; then both group of rats were injected with the
same dose of monoclonal antibody 1-22-3 2 weeks after
the first injection. The rats in the reversible group were
killed just before the injection of monoclonal antibody
1-22-3 and on days 1, 3, 7, and 14 after the first injection
of monoclonal antibody 1-22-3, and on days 1, 3, 7, and
14 days after the second injection of monoclonal anti-
body 1-22-3 in the irreversible group. (N = 5 at each time
point). The presence of lymphocytes in glomeruli was de-
termined by immunofluorescence staining with specific
monoclonal antibodies against the rat lymphocyte anti-
gens described above. Glomerular mRNA expression for
the chemokines [regulated on activation, normal T cell
expressed and secreted (RANTES) and lymphotactin], T
helper 1 (Th1) cytokines [interleukin (IL)-2, interferon-c
(IFN-c)], and T helper 2 (Th2) cytokine (IL-10) were
compared between the reversible group and the irre-
versible group.
Experiment 2: Continuous lymphocyte depletion study.
In vivo T cell depletion was induced by injections of anti-
lymphocyte monoclonal antibody as described above. For
CD5+ cell depletion and CD8+ cell depletion studies,
rats were divided into three groups and five rats of each
group were injected with OX-19 (anti-CD5), OX-8 (anti-
CD8), or RVG1 (control antibody) intraperitoneally
(3 mg/100 g body weight) and intravenously (1 mg/100 g
body weight) simultaneously 2 days before the induction
of irreversible glomerulonephritis, and repeated every
2 weeks for 8 weeks after the second injection of mon-
oclonal antibody 1-22-3. For CD4+ cell depletion study,
another ten rats were divided in two groups and five rats
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Fig. 1. Experiment protocols. Experiment 1 illustrates irreversible
mesangioproliferative glomerulonephritis induced by two injections of
monoclonal antibody (mAb) 1-22-3 in an interval of 2 weeks. Rats were
killed on days specified in the figure, and glomerular leukocyte accu-
mulation was assessed by immunofluorescence method. Experiment 2
shows continuous lymphocyte depletion performed by repeated injec-
tions of antilymphocyte monoclonal antibody. For CD5+ or CD8+ cell
depletion, combined intraperitoneal (i.p.) and intravenous (i.v.) injec-
tion was performed from day 2 and for every 2 weeks. For CD4+ cell
depletion, another intravenous injection was added every week after
the intraperitoneal and intravenous combined injection. A monoclonal
antibody RVG1 was used for the control antibody for each depletion
study. Rats were killed on day 7 or 56 after induction of irreversible
glomerulonephritis, and glomerular alterations and renal injury was as-
sessed. Experiment 3 shows transit lymphocyte depletion performed
by a one-time combined intraperitoneal and intravenous injection of
antilymphocytes monoclonal antibody on day -2. For CD4+ cell deple-
tion, another intravneous injection of OX38 was added a week after the
first injection. All rats were killed 56 days after induction of irreversible
glomerulonephritis, and renal injury was assessed.
of each group were injected with OX-38 (anti-CD4) or
RVG1. Since the OX-38 treatment was not as effective,
rats were given another intravenous injection after every
intraperitoneal and intravneous injection. Twenty-four–
hour urine samples were collected on days 1, 3, 5, 7, 10,
and 14 after the first injection and on days 1, 3, 5, 7, 10,
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Fig. 2. Kinetics of glomerular accumulation of lymphocytes (A to D)
and ED3+ activated macrophage (E) in the reversible model and the
irreversible model. Five rats were killed in each time point after the first
injection (reversible model) and the second injection of monoclonal
antibody (mAb) 1-22-3 (irreversible model). Number of lymphocytes
per glomerular cross section (gcs) were counted in 50 randomly selected
full-size glomeruli. The results were expressed as mean ± SD/gcs (N =
5). ∗P < 0.05; ∗∗P < 0.01 compared with the reversible group at the
same time point.
14, and every week for 8 weeks after the second injec-
tion of monoclonal anitbody 1-22-3. All rats were killed
on day 56 after the second injection of monoclonal an-
tibody 1-22-3, and glomerular lesions were assessed by
light microscopy or immunofluorescence.
Another set of depletion study was performed in the
same protocols. All rats were killed on day 7 after the
second injection of monoclonal antibody 1-22-3, and
the presence of infiltrating cells in glomeruli was as-
sessed by immunofluorescence staining with specific
monoclonal antibodies against rat lymphocyte and
macrophages. Glomerular cytokine production was as-
sessed by a reverse transcription-polymerase chain
reaction (RT-PCR) method on isolated glomeruli by mea-
suring the mRNA expression. The effect of lymphocyte
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Fig. 3. Double staining with anti-CD8 monoclonal antibody (G28) (green) and with anti-CD5 monoclonal antibody (OX-19) (red) of glomerular
sections from rats on the day 7 after the first injection (A) and the second injection (B). No double positive cells were detected in rats of the
reversible group (A), whereas major parts of CD8+ cells were stained with anti-CD5 monoclonal antibody (yellow) in rats of the irreversible group
(B) (original magnification ×400).
depletion was confirmed by flow cytometry using periph-
eral blood.
Experiment 3: Effect of lymophocyte depletion on early
stage of progressive glomerulonephritis. To examine the
effect of lymphocyte depletion for the first 2 weeks of
progressive glomerulonephritis, five rats of four groups
were injected once with antilymphocyte antibody or con-
trol antibody 2 days before the induction of irreversible
glomerulonephritis as described above and left for
8 weeks after the second injection of monoclonal anti-
body 1-22-3. For CD4+ cell depletion, another single in-
travenous injection of anti-OX-38 was given 7 days after
the first injection. All rats were killed 56 days later. Uri-
nary protein extraction and kidney injuries were assessed
in the same way as experiment 2.
Laboratory investigations
Serum creatinine, serum blood urea nitrogen (BUN),
and urinary creatinine levels were measured. From the
data on serum creatinine, urinary creatinine, 24-hour
urine volume, and body weight at sacrifice, the 24-hour
endogenous creatinine clearance was calculated using the
following formula:
Creatinine clearance (mL/min/100 g body weight)
= Urinary creatinine (mg/dL)×
24-hour urine volume (mL)×
1/serum creatinine (mg/dL)×
1440(min) × 1/body weight (g) × 100
Light microscopy
Tissue samples for light microscopic assessment were
fixed with 10% neutral buffered formalin, embedded in
paraffin, cut into 4 lm sections and stained with peri-
odic acid-Schiff (PAS) reagent. Semiquantitative mor-
phologic studies of glomerular lesions were carried out
by randomly selecting 30 full-sized glomeruli (80 to
100 lm) from each specimen. The sections were analyzed
in a double-blind manner and the degree of glomerular
mesangial matrix expansion was scored 0 to 4+ accord-
ing to the percentage of glomerular involvement, as de-
scribed by Raiji, Azar, and Keane [23].
Immunofluorescence
Tissue samples for immunofluorescence studies were
snap-frozen in precooled n-hexane and stored at −70◦C.
Frozen sections 3 lm thick were cut with a cryostat and
stained with specific monoclonal antibodies to rat lym-
phocytes and macrophages described above. The number
of mononuclear cells per glomerular cross section (c/gcs)
was counted in 50 randomly selected full-sized glomeruli
by an observer who was unaware of the experimental
protocol.
To detect CD8+ T lymphocytes, double immunoflu-
orescence studies with OX-19 (anti-CD5; mouse IgG1)
and G28 (anti-CD8; mouse IgG2a) was performed.
Tetramethylrhodamine isothiocynate (TRITC)-conju-
gated goat anti-mouse IgG1 (Southern Biotechnology
Associates) (for OX-19) and FITC-conjugated antimouse
IgG2a (for G28) were used as secondary antibodies. To
quantify the mesangial changes, frozen sections were
stained with anticollagen type I or anti-a-SMA antibod-
ies. The degree of collagen type I and a-SMA staining
was scored 0 to 4+ in 30 randomly selected glomeruli
according to the method described by Floege et al [24].
Flow cytometric analysis
To prepare peripheral blood mononuclear cells, hep-
arinized artery blood was obtained from tail arteries
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Fig. 4. Expression of rat glomerular mRNA for chemokines and lym-
phokines injection with monoclonal antibody (mAb) 1-22-3. The data
shown are representative semiquantitative measurements made by a re-
verse trancription-polymerase chain reaction (RT-PCR) amplification
of mRNA from four rats. mRNA from each rat killed at each time point
was used for RT-PCR (N = 4). Examples of the PCR products obtained
at the selected cycle number for quantification are shown (A). Rela-
tive quantification of lymphotactin (B), regulated on activation, normal
T cell expressed and secreted (RANTES) (C), interleukin (IL)-2 (D),
interferon-c (IFN-c) (E) and IL-10 (F) compared with glyceraldehyde-
3-phophate dehydrogenase (GAPDH) were computed. The data are
shown as mean ± SD (N = 4). ∗P < 0.05 compared with the glomerulus
from rats killed at same time points after the first injection of mono-
clonal antibody 1-22-3.
under general anesthesia. Total mononuclear cells of each
blood sample were counted in triplicate with a hema-
cytometer after being diluted with Turk’s solution. The
contaminating erythrocytes in the cell preparation were
lysed by 0.85% ammonium chloride. FITC-conjugated
OX-19, OX-38, and OX-8 prepared as described by
Kawamura [25], and FITC-conjugated 10/78 (anti-NKR-
P1) (Serotec) were used to detect lymphocyte subsets.
Cytometric analysis of surface antigen expression was
performed on a FACScan (Becton Dickinson, Mountain
View, CA, USA). Total leukocytes were detected using
OX-30 (antileukocyte common antigen marker). RVG1
(mouse IgG1) was used as a negative control.
RT-PCR
Isolated glomeruli were immediately dissociated by
guanidinium and phenol extraction (Trizol) (Gibco BRL,
Gaithesburg, MD, USA). Complementary DNA (cDNA)
was synthesized using a commercial kit (SuperScript
Preamplification System) (Gibco BRL) following the
standard protocol. PCR was performed with the follow-
ing primers: 5′ primer ACC TGC CTC CCC ATA TGG
CT, and 3′ primer GTA TTC TTG AAC CCA CTT CTT
CTT C for RANTES [26]; 5′ primer CCT GGG AGT
CTG CTG CTT CG, and 3′ primer TGG CGG ACC
TCT GGG CTT GT for lymphotactin [27]; 5′ primer
GCG CAC CCA CTT CAA GCC CT, and 3′ primer CCA
CCA CAG TTG CTG GCT CA for IL-2 [28]; 5′ primer
CCC TCT CTG GCT GTT ACT GC, and 3′ primer, CTC
CTT TTC CGC TTC CTT AG for IFN-c [28]; 5′ primer
TGC CTT CAG GAT GTT TGT ACC, and 3′ primer
AAA CTC ATT CAT GGC CTT GTA for IL-10 [28];
5′ primer CGG CTC ACA CTG CCA GCG TAA TGT,
and 3′ primer CCA TCC AGG GTC AGC TGA CAG
GTA for perforin [29]; and 5′ primer CTC TAC CCA
CGG CAA GTT CAA, and 3′ primer GGA TGA CCT
TGC CCA CAG C for glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) [28]. Amplification was carried
out using the PC-800 programmable temperature control
system (Astec, Fukuoka, Japan) through 20 to 40 cycles
of denaturation at 95◦C for 30 seconds, annealing at in-
dividual temperatures for 30 seconds and extension at
72◦C for 1 minute. The optimal cycle numbers were de-
termined in a preliminary trial to be in the linear phase
of amplification. Amplification of the housekeeping gene
GAPDH was used as a positive control for intact RNA
and for measuring the efficiency of RT. Negative con-
trols without cDNA, and positive controls of cDNA from
Con-A–stimulated rat spleen cells, were included in all
experiments. The PCR products were subjected to elec-
trophoresis through 1.5% agarose gels, and stained with
ethidium bromide. The band intensities were determined
by image analysis using a Macintosh computer and den-
sitometry software (Densitograph) (Atto, Tokyo, Japan).
Kidney binding of monoclonal antibody 1-22-3
To compare the amounts of the second injected mono-
clonal antibody 1-22-3 bound to the kidney, total of 12 rats
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Fig. 5. Effect of continuous lymphocyte depletion on renal injuries. Effects of anti-CD5 monoclonal antibody (mAb) (OX-19), anti-CD8
monoclonal antibody (OX-8) (A) and anti-CD4 monoclonal antibody (OX-38) (B) treatments on kinetics of proteinuria in rats after injection of
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were divided into four groups (N = 3 in each treatment
group) and injected with monoclonal antibody 1-22-3 la-
beled with 125I label [30] 2 days after antilymphocyte mon-
oclonal antibody injection. Rats were killed 30 minutes
after the injection of 125I-labeled monoclonal antibody 1-
22-3, and the radioactivity of kidney was measured with
an autogamma scintillation photometer (model 5260)
(Packard, Sterling, VA, USA) 30 minutes after injection.
Statistical analysis
Data were analyzed using StatView for Macintosh
(Abacus Concepts, Berkeley, CA, USA). Comparison be-
tween two groups was evaluated using the Mann-Whitney
U test, and comparison among more than three groups of
animals was performed by one-way analysis of variance
(ANOVA) with individual group means and then com-
pared with the Tukey’s multiple comparison test as post
test. All values were expressed as mean ± SD.
RESULTS
Experiment 1: Comparison of kinetics
of leukocyte infiltration between reversible
and irreversible glomerulonephritis
The kinetics of the recruitment of OX-19 (CD5+), OX-
38 (CD4+), OX-8 (CD8+), or 10/78 (NKR-P1+) cells are
shown in Figure 2. Significant increases in the number of
lymphocytes indicated by the presence of CD5+, CD4+,
CD8+, and NKR-P1+ cells were observed in glomeruli
and peaked on day 7 after the single injection of mon-
oclonal antibody 1-22-3. The number of CD5+ cells on
days 1 and 3 and CD4+ cells on day 3 in the irreversible
model were significantly higher than those in the animals
of the reversible model at the same time points. The num-
ber of CD8+ cells on days 1 and 3 was also significantly
higher in the irreversible group; however, the number of
NKR-P1+ cells was not different (Fig. 2A to D).
Double-staining immunofluorescence study demon-
strated that CD8+ cells detected in the glomeruli from
animals of the reversible group were negative of CD5
(Fig. 3A), while a part of CD8+ cells in the glomerulus
from the irreversible group were also stained with CD5
(Fig. 3B), indicating that CD8 T cells accumulated only
in the glomeruli of the irreversible group.
The number of ED3+-activated macrophage was sig-
nificantly higher in the irreversible group at all points in
time (Fig. 2E).
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
monoclonal antibody 1-22-3. Results were expressed as mean ± SD (N = 5). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 compared with the control group at
the same time point. Effects of treatment on renal injuries evaluated by matrix expansion (C), collagen type I staining score (D), a-smooth muscle
actin (a-SMA) staining score (E), creatinine clearance (CCr) (mL/min/100 g body weight) (F), serum level of blood urea nitrogen (BUN) (G), and
kidney weight (/100 g body weight) (H) were compared between the lymphocyte-depleted group, and age-matched normal rats or disease control
rats on day 56. Each value is expressed as mean ± SD (N = 5). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 compared with RVG1 group by one-way analysis
of variance (ANOVA) with individual group means ten computed with Tukey’s multiple comparison test.
Glomerular expression of mRNA for both lympho-
tactin and RANTES was observed more quickly after
the second injection of monoclonal antibody 1-22-3, and
the expression was prolonged until day 14 (Fig. 4B and
C). The mRNA expression for IL-2 and IFN-c in the irre-
versible model was significantly higher than in the animals
of the reversible model at the same time points (Fig. 4D
and E). Increase of mRNA for IL-10 was also detected
7 and 14 days after the second injection of monoclonal
antibody 1-22-3 (Fig. 4F).
Experiment 2: Continuous lymphocyte depletion study
The change in degree of proteinuria over time is il-
lustrated in Figure 5A and B. Significant reduction of
proteinuria from day 14 after the second injection of
monoclonal antibody 1-22-3 was observed in the anti-
CD5 monoclonal antibody (OX-19) and anti-CD8 mon-
oclonal antibody (OX-8)-treated groups. The proteinuria
in the anti-CD4 monoclonal antibody (OX-38)-treated
animals was reduced significantly 10 days after the sec-
ond injection of monoclonal antibody 1-22-3. A com-
parison of the mesangial injury evaluated by a matrix
score, a-SMA staining score and collagen type I staining
score, creatinine clearance, serum level of BUN, and kid-
ney weight on day 56 is summarized in Figure 5C to H.
Anti-CD5 treatment, anti-CD4 treatment, and anti-CD8
treatment prevented mesangial cell alterations. Renal
function evaluated by creatinine clearance and serum
level of BUN was significantly reduced in RVG1-treated
disease control rats compared with normal rats, while
continuous lymphocyte depletion, including anti-CD5
treatment, anti-CD4 treatment, and anti-CD8 treatment,
prevented the reduction of renal function. These antilym-
phocyte treatments also prevented the increase of kidney
weight. Figure 6 shows representative findings of kidney
sections from disease control rats (Fig. 6A, C, and E) and
anti-CD5-treated rats (Fig. 6B, D, and F).
Amount of monoclonal antibody 1-22-3 bound to
glomeruli. To ascertain whether the antilymphocyte
treatments might interfere with the binding of mono-
clonal antibody 1-22-3 to a kidney, the radioactivity of
125I-labeled monoclonal antibody 1-22-3 was measured
in a c counter. In the group of rats treated with anti-
CD5 monoclonal antibody, anti-CD8 monoclonal anti-
body, anti-CD4 monoclonal antibody, and RVG1 control,
the mean amounts of monoclonal antibody 1-22-3 bound
in a kidney were 19.37 ± 0.80 lg, 19.16 ± 0.80 lg, 20.24 ±
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A B
D
F
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E
Fig. 6. Micrographs of kidney sections from
a control (RVG1-treated) group (A to C)
and from rats treated with anti-CD5 mon-
oclonal antibody (mAb) (OX-19) (D to F)
56 days after the second injection of mon-
oclonal antibody 1-22-3. Micrograph of pe-
riodic acid-Schiff (PAS)-stained (A and B)
and immunofluorescence micrograph of anti-
type I collagen (C and D) and anti-a-smooth
muscle actin (a-SMA) (E and F) on the day
56 after the second injection of monoclonal
antibody 1-22-3. Mesangial cell proliferation
and severe matrix expansion are detected in
RVG1 control rats (A), whereas light mi-
croscopy findings of anti-CD5 monoclonal
antibody–treated rats were almost normal-
ized (B). Intense staining of collagen type
I or a-SMA was detected in RVG1-treated
rats, whereas the staining of collagen type I
or a-SMA in anti-CD5 monoclonal antibody–
treated rats was weak (original magnification,
×200).
Table 1. Cell numbers in circulating lymphocyte subpopulations in lymphocyte-depleted and control-treated rats 7 days after the second injection
of monoclonal antibody 1-22-3
Treatment Total cells CD5 CD4 CD8 NK
Control (RVG1) 7500.5 ± 950.2 4571.3 ± 670.4 3753.6 ± 565.0 1713.73 ± 489.6 481.0 ± 86.7
Anti-CD5 (OX-19) 3992.5 ± 166.3a 22.0 ± 2.9a 646.7 ± 75.2a 1162.7 ± 129.0b 537.7 ± 82.5
Anti-CD4 (OX-38) 5449.2 ± 435.8a 2156.1 ± 535.4a 1656.5 ± 464.3a 1372.2 ± 233.5 419.5 ± 59.7
Anti-CD8 (OX-8) 6348.3 ± 1526.1 3858.5 ± 674.2 3716.2 ± 654.2 20.1 ± 8.5a 13.7 ± 8.0a
NK is natural killer. Data are expressed as mean ± SD (cells/mL) (N = 5).
aP < 0.001; bP < 0.05 compared with control (RVG1)-treated rats.
3.38 lg, and 19.07 ± 2.08 lg, respectively, and there were
no significant differences between these groups.
Flow cytometry. Cell numbers in the circulating lym-
phocyte subpopulations in the leukocyte-depleted and
control groups 7 days after induction of irreversible
glomerulonephritis are summarized in Table 1. In the pe-
ripheral blood, anti-CD5 monoclonal antibody (OX-19)
treatment caused marked reductions in the numbers of
CD5+ and CD4+ cells. This treatment also reduced the
numbers of CD8+ cells, suggesting that anti-CD5 mon-
oclonal antibody treatment affects both CD4+ T cells
and CD8+ T cells. Anti-CD4 treatment also reduced the
number of CD5+ and CD4+ cells, but did not affect the
number of CD8+ cells. Anti-CD8 monoclonal antibody
(OX-8) affected the numbers of both CD8+ cells and
NKR-P1+ cells but had no effect on CD4+ cell count.
Circulating lymphocyte populations in control (RVG1)-
treated rats were unaffected. There was no change in the
efficacy of the antilymphocyte treatment on day 56 (data
not shown).
Effect of antilymphocyte treatment on glomerular
leukocyte accumulation. Immunofluorescence staining
of glomeruli from each treatment group on day 7 re-
vealed that the anti-CD5 monoclonal antibody treatment
1044 Ikezumi et al: Lymphocytes in progressive glomerulonephritis
0
1
2
3
4
5
CD
5+
 c
el
ls/
gc
s
***
*** ***
A
0
1
2
3
4
5
CD
4+
 c
el
ls/
gc
s
***
***
***
B
0
1
2
3
4
5
CD
8+
 c
el
ls/
gc
s
***
***
***
C
0
1
2
3
4
5
N
KR
-P
1+
 c
el
ls
/g
cs
***
D
0
1
2
CD
5+
 C
D8
+ 
ce
lls
/g
cs
***
***
***
E
RV
G1
an
ti-C
D5
an
ti-C
D4
an
ti-C
D8
0
5
10
CD
16
9+
 c
el
ls/
gc
s
***
***
F
RV
G1
an
ti-C
D5
an
ti-C
D4
an
ti-C
D8
Fig. 7. Effects of lymphocyte depletion on rat glomerular leukocyte
accumulation on day 7 after injection of monoclonal antibody (mAb) 1-
22-3. The glomerular infiltration by OX-19 (CD5+) (A), OX-38 (CD4)+
(B), OX-8 (CD8+) (C), 10/78 (NKR-P1+) (D), CD5+ CD8+ dual pos-
itive cells (CD8 T cells) (E), and ED3+ (CD169) (sialoadhesin) (F)
cells were compared by immunofluorescence staining. CD5+ CD8+
dual positive cells were counted by double-staining immunofluores-
cence method. Values are expressed as mean ± SD. ∗∗∗P < 0.001 com-
pared with the control group at the same time point.
prevented the glomerular influx of CD5+ cells and CD4+
cells as well as CD8+ cells, but did not affect the number
of NKR-P1+ cells, suggesting that this treatment affected
on both CD4+ and CD8+ T lymphocytes but not NK
cells. The anti-CD4 treatment also reduced the number of
CD5+ cells and CD4+ cells. Interestingly, this treatment
also reduced the glomerular influx of CD8+ cells (Fig. 7).
The anti-CD8 treatment prevented the glomerular influx
of CD5+ cells, CD8+ cells, and NKR-P1+ cells, but did
not affect the number of CD4+ cells. Double-labeling im-
munofluorescence study showed that not only anti-CD5
treatment and anti-CD8 treatment but also anti-CD4
treatment reduced the number of CD5+ CD8+ cells, sug-
gesting that anti-CD4 treatment affects glomerular accu-
mulation of CD8 T cells (Fig. 7E). Both anti-CD5 and
anti-CD4 treatments also reduced glomerular accumula-
tion of ED3+ macrophage (activated macrophage). The
anti-CD8 treatment did not affect the number of ED3+
cells (Fig. 7F).
RT-PCR. RT-PCR (Fig. 8) showed that both the anti-
CD5 and anti-CD4 treatments reduced the glomerular
expression of mRNA for IL-2 (anti-CD5 70% reduction
and anti-CD4 50% reduction, respectively) and for IFN-
c (anti-CD5 63.0% and anti-CD4 62.3%, respectively).
The anti-CD8 treatment also reduced glomerular IFN-c
mRNA expression by 62%, although this treatment did
not affect mRNA expression for IL-2. mRNA expression
for perforin was reduced by the anti-CD5 treatment and
anti-CD8 treatment but not by the anti-CD4 treatment,
suggesting that the perforin was produced by glomerular
CD8+ T cells.
Experiment 3: Effect of lymphocyte depletion during
early stage of irreversible glomerulonephritis
Both the anti-CD5 treatment and anti-CD4 treatment
given once on day 2 reduced proteinuria (Fig. 9A) and
prevented renal injuries 56 days after the second injection
of monoclonal antibody 1-22-3, while the transit anti-CD8
treatment could not reduce proteinuria nor glomerular
alterations (Fig. 9B to F). Only anti-CD5 treatment pre-
vented the increase of kidney weight (Fig. 9G).
DISCUSSION
The present study clearly demonstrated that both
CD4+ T cells and CD8+ T cells are essential for
the development of progressive mesangial proliferative
glomerulonephritis induced in rats. CD4+ T cells play an
essential role in the early phase, while CD8+ T cells may
be mainly involved in the progression of disease in the
later phase.
Previously, we had analyzed the role of T lymphocyte
in the development of glomerulonephritis in a rat model
caused by a single injection of anti-Thy 1.1 monoclonal
antibody 1-22-3 [10]. We demonstrated that CD4+ T lym-
phocytes play a critical role in the development of the
glomerulonephritis. However, because the model used in
the previous study was a reversible model, the role of
lymphocyte in the development of the progressive
glomerulonephritis remains unanswered. In this study, we
investigated the role of lymphocytes in the development
of irreversible glomerular alteration induced by two con-
secutive injections of monoclonal antibody 1-22-3 in the
interval of 2 weeks.
We believe that comparing the inflammatory responses
between the reversible and the irreversible models is a
successful way to identify the essential factor in bringing
about the irreversible alterations. Therefore, we began
with the comparison of the kinetics of lymphocytes ac-
cumulation between the reversible and the irreversible
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Fig. 8. Effects of lymphocyte depletion on
glomerular cytokine expression on day 7 after
the second injection of monoclonal antibody
(mAb) 1-22-3. The data shown are representa-
tive semiquantitative measurements made by
reverse transcription-polymerase chain reac-
tion (RT-PCR) amplification of mRNA from
five rats. mRNA from five rats killed at each
time point was pooled and used for RT-
PCR. The representative agarose gel elec-
trophoretic patterns from one of three inde-
pendent experiments were shown (A). Ratios
of the densitometric signals of cytokines to
that of the internal control [glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)] were
computed. The data are shown as ratios rel-
ative to normal rat findings and expressed
as mean ± SD of three independent exper-
iments (B to D). Abbreviations are: INF-c,
interferon-gamma; IL-2, interleukin 2. ∗∗∗P <
0.001 compared with RVG1 group by one-way
analysis of variance (ANOVA) with individ-
ual group means ten computed with Tukey’s
multiple comparison test.
models. Immunofluorescence studies with monoclonal
antibodies recognizing subpopulations of lymphocytes
revealed that the number of glomerular CD5+ cells,
CD8+ cells, and CD4+ cells, but not that of NKR-P1+
cells, was significantly higher in the irreversible model
(Fig. 2). Double-staining immunofluorescence studies re-
vealed that, in the reversible model, most CD8+ cells de-
tected in the glomeruli were NK cells rather than CD8+
T lymphocytes, which was consistent with our previous
study [10]. On the other hand, there was a marked in-
crease of glomerular accumulation of CD8+ T lympho-
cytes (CD8/CD5 double-positive cells) in the irreversible
model (Fig. 3). It has been demonstrated that CD8+ cy-
totoxic T lymphocytes express potent cytotoxic activity
in vitro and in experimental glomerulonephritis mod-
els [31–33]. Thus, the evidence of the increased number
of the glomerular CD8+ T cells, which were observed
only in the irreversible group, suggested the contribution
of CD8+ T cells in the development of the progressive
glomerular injuries. Because no differences in the mesan-
gial alterations on day 7 of the reversible and irreversible
models were detected with a light microscopic study, we
consider that CD8+ T cells in glomeruli could be a useful
index to predict disease progression.
We also found that the peak number of ED3+ cells
in glomeruli of the irreversible model was significantly
larger than that of the reversible model (Fig. 2E). ED3
is known to detect macrophage CD169, sialoadhesin, a
marker of activated macrophages, which may participate
in the pathogenesis of inflammatory disease, including
several types of glomerulonephritis [34–36]. Thus, the
significant increase of sialoadhesin-positive macrophage
also could be an important candidate in inducing irre-
versible alteration of glomeruli.
To clarify the role of these lymphocytes, we performed
lymphocyte depletion studies by two different protocols
to assess the phase-dependent roles of CD4+ T cell and
CD8+ T cell. First, we performed a continuous deple-
tion study, which deplete lymphocytes from the begin-
ning to the end of the experiment. Results showed that
the continuous CD8+ cell depletion as well as the CD5+
or CD4+ T-lymphocyte depletion reduced proteinuria
and prevented renal injuries (Fig. 5). All treatments dra-
matically reduced the mesangial expansion and fibrotic
change of glomeruli on day 56.
Second, we performed transit lymphocyte depletion
studies, in which the effect of antilymphocyte mono-
clonal antibody was limited in the early stage of irre-
versible glomerulonephritis (just 2 weeks after the sec-
ond injection of monoclonal antibody 1-22-3). The result
showed that anti-CD4 and anti-CD5 treatments, but not
anti-CD8 treatment, reduced proteinuria and prevented
glomerular alterations on day 56. Despite the fact that
a single anti-CD8 administration completely prevented
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Fig. 9. Effect of transit lymphocyte depletion on renal injuries. Effects of antilymphocyte treatments on kinetics of proteinuria in rats after injection
of monoclonal antibody (mAb) 1-22-3 were summarized (A). Results were expressed as mean ± SD (N = 5). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001
compared with the control group at the same time point. Renal injuries evaluated by matrix expansion (B), collagen type I staining score (C),
a-smooth muscle actin (a-SMA) staining score (D), creatinine clearance (CCr) (mL/min/100 g body weight) (E), serum level of blood urea nitrogen
(BUN) (F), and kidney weight (/100 g body weight) (G) were compared between the lymphocyte-depleted group and the control group on day 56.
Each value is expressed as mean ± SD (N = 5). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 compared with RVG1 group by one-way analysis of variance
(ANOVA) with individual group means ten computed with Tukey’s multiple comparison test.
glomerular accumulation of CD8+ T cells until day 7,
this treatment could not prevent the consequent disease
progression in glomeruli. Thus, continuous depletion of
CD8+ T cells could ameliorate glomerular injury, sug-
gesting that CD8+ T cells play their role in the late phase
of progressive glomerulonephritis.
An interesting finding was that the specific antilympho-
cyte treatment reduced not only corresponding cells but
also related cells (Fig. 7). For example, anti-CD4 treat-
ment reduced not only CD4+ T cells but also CD8+
T cells and ED3+ macrophage. The anti-CD5 mon-
oclonal antibody treatment and anti-CD4 monoclonal
antibody treatment, but not the anti-CD8 monoclonal
antibody treatment decreased the number of ED3+ cells
in glomeruli on day 7 after the second injection of mon-
oclonal antibody 1-22-3, suggesting that CD5+ CD4+
cells (CD4 T lymphocytes) contribute to the recruitment
and/or activation of ED3+ cells. Taking together all these
findings, both CD8+ T cells and ED3+ macrophage con-
tributed to glomerular alterations in the late phase of
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disease progression, and the recruitment and/or activa-
tion of these cells were controlled by the CD4+ T cells
recruited in early phase.
It is well known that activated CD4+ T cells direct
the immune response by stimulating various cells. In this
study, we demonstrated that the mRNA expression for
IL-2 and IFN-c in the irreversible model was significantly
higher than in the reversible model (Fig. 4). We also
demonstrated that depletion of CD4+ T cells resulted
in a reduction of glomerular expression of mRNA for
IFN-c and IL-2. Both IFN-c and IL-2 are known as Th1
cytokines, which present proinflammatory effects and ac-
tivate macrophages, cytotoxic CD8+ T cells, and NK cells,
as well as resident renal cells. These results suggested
that Th1 cytokines play an essential role for the devel-
opment of disease in the irreversible model. Both CD8+
T cells and NK cells can produce IFN-c [37]. Indeed, we
demonstrated that anti-CD8 treatment, which depletes
both CD8+ T cell and NK cell, reduced glomerular ex-
pression for IFN-c mRNA (Fig. 8). Recently, IFN-c has
been shown to augment macrophage-mediated glomeru-
lar injury [38, 39], and it has also been reported as an
essential cytokine in the crescentic glomerulonephritis,
in which macrophage might play the central role by re-
sponding to the stimulation of IFN-c [40, 41]. These re-
ports indicate that there was an intimate interplay be-
tween macrophage and lymphocytes in the progression
of renal disease, and the inflammatory cytokines, includ-
ing IFN-c intermediate between these cells. Macrophage
and cytotoxic CD8+ T cells, once activated, may produce
a great deal of cytotoxic mediator, such as reactive oxygen
species, nitric oxide, and perforin. Continuous expression
of these cytokine would induce irreversible glomerular
alterations.
The mechanism by which regulate glomerular recruit-
ment of CD8+ T cells and ED3+-activated macrophage
has not been clarified yet. However, it is possible that
different immune responses come in the irreversible
model after the second injection of monoclonal anti-
body 1-22-3 and induce reaction of mesangial cells to se-
cret chemokines, which attract these inflammatory cells
[27, 42]. Among many kinds of chemokine produced by
mesangial cell, lymphotactin has been known to be a
specifically chemotactic factor for lymphocytes, includ-
ing CD4+, CD8+ T lymphocytes, and NK cells [43]. Ac-
tivated CD8+ T cells, in turn, produce large quantities
of lymphotactin, which may attract additional CD8+ T
cells and CD4+ T cells. RANTES also has been known to
attract lymphocytes and monocytes into sites of inflam-
mation [44]. In the present study, we demonstrated that
there was increased and prolonged expression of both
lymphotactin and RANTES mRNA in glomeruli after the
second injection of monoclonal antibody 1-22-3 (Fig. 4),
supporting the idea that these chemokines were playing
an essential role in the recruitment of lymphocyte in pro-
gressive glomerulonephritis. Thus, these chemokines pro-
duced in glomeruli during the early phase of progressive
glomerulonephritis also could be important targets for
the treatment.
CONCLUSION
This study demonstrated that lymphocytes played es-
sential roles in the progression of irreversible mesangial
proliferative glomerulonephritis. We clearly showed that
initial recruitment of CD4+ T cells controlled the con-
sequent recruitment and/or activation of CD8+ T cells
and macrophages that also contributed to the progres-
sion of irreversible glomerulonephritis. We believe that
early treatment against lymphocyte could prevent conse-
quent progression of chronic glomerulonephritis.
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